Show simple item record

AuthorVolden, Matthiasdc.contributor.author
Date of accession2016-03-15T10:41:31Zdc.date.accessioned
Available in OPARU since2016-03-15T10:41:31Zdc.date.available
Year of creation2013dc.date.created
AbstractIntroduction: The application of monoclonal antibodies has become standard of care in the treatment of Chronic lymphocytic leukemia (CLL). We compared the single-agent-activity of three currently approved therapeutic antibodies for CLL, namely Rituxi-mab, Alemtuzumab, and Ofatumumab. Question: Our goal was to identify underlying mechanisms of action of monoclonal antibodies in CLL in order to recognize potential limitations of their use and to develop strategies to overcome these limitations or at least to use the antibodies in the most beneficial way. We had our major focus on the impact of genetic subgroups of CLL and on Ofatumumab, a relatively new CD20-antibody in comparison with Rituximab and Alemtuzumab. Method: Patient samples were analysed by flow cytometry, fluorescence in-situ hybridiziation, liquid chromatography, and classic sequencing. Antibody-treatment was performed in both cell culture and whole blood assays. We assessed CLL-cell-viability, homotypic adhesion, potential synergism with other substances, and the impact of the cellular micro-environment by co-culturing CLL cells with fibroblastoid stroma cells. In parallel, CLL-cell-concentration, and effector consumption were assessed. Read out methods comprised microscopy, multi-color flow cytometry and luminometry. Results: Rituximab, Alemtuzumab, and Ofatumumab showed varying activity and different mechanisms of action. Regarding each antibody individually, no considerable difference could be detected among different risk-stratified CLL subgroups. In a sub-group of patients, we mimicked in vivo micro-environment by coincubation of CLL cells with HS5-cells and discovered a decrease of Alemtuzumab-activity but not Ofatumumab-activity. Summary: Ofatumumab seems highly suitable for various combinations and high-risk CLL patients might benefit of those. Based on our in vitro findings, we suggest several strategies to enhance in vivo Ofatumumab activity.dc.description.abstract
Languageendc.language.iso
PublisherUniversität Ulmdc.publisher
LicenseStandarddc.rights
Link to license texthttps://oparu.uni-ulm.de/xmlui/license_v3dc.rights.uri
KeywordAlemtuzumabdc.subject
KeywordCD20dc.subject
KeywordCDCdc.subject
KeywordOfatumumabdc.subject
KeywordRituximabdc.subject
Dewey Decimal GroupDDC 610 / Medicine & healthdc.subject.ddc
MeSHAntibodies, monoclonaldc.subject.mesh
MeSHAntibodies, monoclonal, humanizeddc.subject.mesh
MeSHAntibodies, monoclonal, murine-deriveddc.subject.mesh
MeSHLeukemia, lymphatic, chronic, B-celldc.subject.mesh
MeSHLeukemia, lymphocytic, chronic, B-celldc.subject.mesh
TitleOfatumumab: Evaluation of in-vitro response mechanismsdc.title
Resource typeDissertationdc.type
DOIhttp://dx.doi.org/10.18725/OPARU-3419dc.identifier.doi
PPN1658711998dc.identifier.ppn
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-vts-91116dc.identifier.urn
GNDChronisch-lymphatische Leukämiedc.subject.gnd
FacultyMedizinische Fakultätuulm.affiliationGeneral
Date of activation2014-07-24T11:32:41Zuulm.freischaltungVTS
Peer reviewneinuulm.peerReview
Shelfmark print versionW: W-H 13.737uulm.shelfmark
DCMI TypeTextuulm.typeDCMI
VTS ID9111uulm.vtsID
CategoryPublikationenuulm.category
Bibliographyuulmuulm.bibliographie


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record